These tests are expensive and less available in some healthcare settings since they frequently require neuropsychologists or other specialised professionals for administration and interpretation [23]. When it comes to the existence of specific biomarkers linked to Alzheimer's disease, including beta-amyloid and tau proteins, CSF examination can offer helpful information. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.